User login
Key clinical point: Presence of SRSF2 mutations in patients with acute myeloid leukemia (AML) did not affect clinical outcomes after allogeneic hematopoietic stem cell transplantation (HSCT).
Major finding: Overall, 12.5% of patients harbored an SRSF2 mutation that persisted in 93% of analyzed patients in remission prior to HSCT. SRSF2 P95 mutation at diagnosis and HSCT did not affect the cumulative incidence of relapse (both P = .68), event-free survival (P = .40 and P = .80, respectively), or overall survival (P = .10 and P = .90, respectively) in patients with AML consolidated with HSCT in complete remission (CR) or CR with incomplete peripheral recovery.
Study details: Findings are from a retrospective analysis of 263 adult patients with AML who underwent allogeneic HSCT between May 2000 and August 2020.
Disclosures: This work was supported by the Deutsche José-Carreras-Stiftung, Deutsche Gesellschaft für Innere Medizin, Verein zusammen gegen den Krebs e.V., and Ein Herz für Kinder e.V. The authors declared no conflict of interests.
Source: Grimm J et al. Am J Hematol. 2021 Jul 21. doi: 10.1002/ajh.26298.
Key clinical point: Presence of SRSF2 mutations in patients with acute myeloid leukemia (AML) did not affect clinical outcomes after allogeneic hematopoietic stem cell transplantation (HSCT).
Major finding: Overall, 12.5% of patients harbored an SRSF2 mutation that persisted in 93% of analyzed patients in remission prior to HSCT. SRSF2 P95 mutation at diagnosis and HSCT did not affect the cumulative incidence of relapse (both P = .68), event-free survival (P = .40 and P = .80, respectively), or overall survival (P = .10 and P = .90, respectively) in patients with AML consolidated with HSCT in complete remission (CR) or CR with incomplete peripheral recovery.
Study details: Findings are from a retrospective analysis of 263 adult patients with AML who underwent allogeneic HSCT between May 2000 and August 2020.
Disclosures: This work was supported by the Deutsche José-Carreras-Stiftung, Deutsche Gesellschaft für Innere Medizin, Verein zusammen gegen den Krebs e.V., and Ein Herz für Kinder e.V. The authors declared no conflict of interests.
Source: Grimm J et al. Am J Hematol. 2021 Jul 21. doi: 10.1002/ajh.26298.
Key clinical point: Presence of SRSF2 mutations in patients with acute myeloid leukemia (AML) did not affect clinical outcomes after allogeneic hematopoietic stem cell transplantation (HSCT).
Major finding: Overall, 12.5% of patients harbored an SRSF2 mutation that persisted in 93% of analyzed patients in remission prior to HSCT. SRSF2 P95 mutation at diagnosis and HSCT did not affect the cumulative incidence of relapse (both P = .68), event-free survival (P = .40 and P = .80, respectively), or overall survival (P = .10 and P = .90, respectively) in patients with AML consolidated with HSCT in complete remission (CR) or CR with incomplete peripheral recovery.
Study details: Findings are from a retrospective analysis of 263 adult patients with AML who underwent allogeneic HSCT between May 2000 and August 2020.
Disclosures: This work was supported by the Deutsche José-Carreras-Stiftung, Deutsche Gesellschaft für Innere Medizin, Verein zusammen gegen den Krebs e.V., and Ein Herz für Kinder e.V. The authors declared no conflict of interests.
Source: Grimm J et al. Am J Hematol. 2021 Jul 21. doi: 10.1002/ajh.26298.